Lv1
73 积分 2021-02-02 加入
Epstein–Barr virus exploits desmocollin 2 as the principal epithelial cell entry receptor
19天前
已完结
The performance of abbreviated comprehensive geriatric assessment in elderly patients with diffuse large B cell lymphoma
1个月前
已完结
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi
1个月前
已完结
ABCL-942: Pola-R-Mini-CHP for Untreated Diffuse Large B-Cell Lymphoma in Patients Who Are Elderly With Comorbid Conditions
1个月前
已关闭
Beta2-microglobulin is a valuable marker and identifies a poor-prognosis subgroup among intermediate-risk patients with diffuse large B cell lymphoma
1个月前
已完结
Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B‐Cell Lymphoma: A Real‐World, Multi‐Center, Retrospective Cohort Study
5个月前
已完结
Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B‐Cell Lymphoma: A Real‐World, Multi‐Center, Retrospective Cohort Study
5个月前
已完结
Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B‐Cell Lymphoma: A Real‐World, Multi‐Center, Retrospective Cohort Study
5个月前
已完结
Effectiveness and safety of polatuzumab vedotin combined with zuberitamab plus cyclophosphamide, doxorubicin and prednisone in untreated diffuse large B-cell lymphoma: A real-world study from China
6个月前
已关闭
[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant]
10个月前
已关闭
皖公网安备34019202002308
